Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
This approach may be relevant for vivo studies focused on regenerative pathways, inflammatory response, injury recovery, or digestive system function
doi: 10.1007/s00394-014-0662-7
When the researchers factored in duration of use in secondary analyses, they did detect an increased risk of breast cancer when patients had used GLP-1 analogues for between 2.1 and 3.0 years (hazard ratio [HR] 2.7) and when the time since initiation was between 3.1 and 4.0 years (HR 2.6)
US$ 23.07
US$ 21.89
US$ 22.60
US$ 28.65
